Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.55 USD | +0.21% | +4.81% | -7.40% |
05:14pm | Roche: efficacy of Evrysdi in spinal muscular atrophy | CF |
05:12pm | Roche's Five-year Data Confirms Efficacy, Safety of Evrysdi Drug for Spinal Muscular Atrophy in Children | MT |
Sales 2024 * | 60.39B 67.34B | Sales 2025 * | 63.83B 71.18B | Capitalization | 193B 215B |
---|---|---|---|---|---|
Net income 2024 * | 13.27B 14.8B | Net income 2025 * | 14.76B 16.46B | EV / Sales 2024 * | 3.42 x |
Net Debt 2024 * | 13.77B 15.36B | Net Debt 2025 * | 7.88B 8.79B | EV / Sales 2025 * | 3.14 x |
P/E ratio 2024 * |
14
x | P/E ratio 2025 * |
12.7
x | Employees | 103,605 |
Yield 2024 * |
4.11% | Yield 2025 * |
4.23% | Free-Float | 88.91% |
Latest transcript on Roche Holding AG
1 day | +0.21% | ||
1 week | +4.81% | ||
Current month | +4.81% | ||
1 month | +10.07% | ||
3 months | -0.65% | ||
6 months | -5.71% | ||
Current year | -7.40% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 95-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 33.55 | +0.21% | 3 674 461 |
24-06-06 | 33.48 | +1.33% | 1,585,172 |
24-06-05 | 33.04 | +0.46% | 1,624,941 |
24-06-04 | 32.89 | +1.70% | 2,209,883 |
24-06-03 | 32.34 | +1.03% | 2,066,509 |
Delayed Quote OTC Markets, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.82% | 754B | |
+40.95% | 630B | |
-6.16% | 352B | |
+19.86% | 331B | |
+9.32% | 298B | |
+18.45% | 250B | |
+11.88% | 217B | |
+5.90% | 164B | |
-0.73% | 163B |
- Stock Market
- Equities
- ROG Stock
- RHHBY Stock